Menu
ETF
Annual · values202520242023202220212020201920182017201620152014
Operating Cash Flow-46000 USD-8.00 M USD-16.95 M USD-18.71 M USD-16.26 M USD-13.11 M USD-12.84 M USD-10.03 M USD-9.15 M USD-7.92 M USD-8.63 M USD-3.85 M USD
Depreciation & Amortization0 USD161000 USD212000 USD404000 USD205000 USD148000 USD115000 USD147000 USD157000 USD130000 USD92000 USD78000 USD
Stock-Based Compensation-12000 USD12000 USD-57000 USD879000 USD491000 USD408000 USD516000 USD-65000 USD726000 USD1.21 M USD3.72 M USD312000 USD
Capital Expenditures83000 USD486000 USD1.01 M USD379000 USD167000 USD94000 USD231000 USD166000 USD270000 USD46000 USD
Cash Flow from Investing48000 USD-840000 USD21.36 M USD-12.51 M USD-16.01 M USD-10.45 M USD5.45 M USD-5.72 M USD-231000 USD4.69 M USD-5.07 M USD-46000 USD
Cash Flow from Financing8.85 M USD51.02 M USD23.58 M USD6.51 M USD17.76 M USD4.58 M USD5.42 M USD22.01 M USD
Dividends Paid
Stock Buybacks
Free Cash Flow-17.04 M USD-19.19 M USD-17.27 M USD-13.49 M USD-13.01 M USD-10.13 M USD-9.38 M USD-8.09 M USD-8.90 M USD-3.90 M USD

Check-Cap Ltd. is a clinical-stage medical diagnostics company based in Israel, specializing in the development of innovative capsule-based screening technology for colorectal cancer detection. Founded in 2004, the company focuses on its proprietary C-Scan system, which includes an ingestible capsule that uses ultra-low-dose X-rays to non-invasively scan the inner lining of the colon for precancerous polyps and structural abnormalities. This capsule-based approach aims to provide patient-friendly, preparation-free colorectal screening to increase adherence and enable early intervention. The system comprises the C-Scan capsule, a disposable tracking device attached externally to the patient, and analytic software for data processing and report generation. Check-Cap's technology represents a significant advancement in non-invasive cancer diagnostics, aligning with the broader healthcare sector's focus on early detection and preventive medicine.